Rewired.GG Makes Europe’s Largest Ever esports Team Investment
Rewired.GG, the €50m esports venture fund that invests in the global growth of esports, is delighted to announce that it has invested a further €14 million into Team Vitality, taking its total investment to date to €34 million. Today also marks the opening of the new multi-million euro Team Vitality headquarters in Paris, called V.Hive, which will be open to the public. In a world’s first for an esports team, the 10,700 sq ft V.Hive has more than 530 sq ft of store front in the bustling heart of Paris, and will offer engaging esports discoveries and experiences to anyone who walks in.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191106005183/en/
Team Vitality Counter Strike players (from left to right): Alex 'ALEX' McMeekin, Cédric 'RpK' Guipouy, Mathieu 'ZywOo' Herbaut, Dan 'apEX' Madesclaire. (Photo: Business Wire)
Team Vitality is one of the biggest esports teams in Europe and boasts some of the world’s top esports players and coaches. It is one of only ten European esports teams in the League of Legends European Championship franchise; and has recently won the 2019 World Championship for Rocket League, won the 7th season of the prestigious ECS tournament for Counter-Strike:Global Offensive and took 3rd place in the 2019 FIFA World Championship. It is also one of only a few esports teams with blue chip sponsors such as Orange, Renault, Red Bull and adidas.
Rewired.GG forecasts that esports will rival traditional sports such as soccer and basketball and will be a major investment category for institutional investors, funds and investment managers. By 2020 it is estimated that the monthly global esports audience size will be nearly 600 million*, equivalent to the current global audience of the English Premier League.
Today’s investment, along with the €20 million that Team Vitality received from Rewired.GG in November 2018, is thought to be the largest investment into a European esports team to date. The Team, which was founded in 2013 with €10,000, aims to be one of the world’s first $1 billion esports teams.
The funds will be used to support the continued growth of Team Vitality as the team pursues further expansion across India and China, where it is acquiring new players and launching a network of esports academies. Funds will also be used to acquire new players and to launch new lines of merchandise globally: as well as opening V.Hive, the team has also today launched its first Team Vitality brand of limited-edition adidas trainers.
As with any major sport, the business of esports is based on media rights, advertising, prize money, merchandise, sponsorship and partnerships. Revenue from these are growing exponentially.
In 2017 it was estimated that esports generated $655 million in annual revenue, including 38% from sponsorships and 14% from media rights. By 2022, it is forecast that media rights will reach 40% of total esports revenue and that total global esports monetization will reach $3bn.*
CEO of Team Vitality, Nicolas Maurer said:
“In 2013 we started Team Vitality with €10,000. Today Team Vitality has built amazing teams that regularly win tournaments all over the world, and a strong brand that is backed by our amazing and dedicated fans and our premium sponsors. Receiving further backing by Rewired.GG after the initial investment of €20M in November 2018 is a testament to the strength not only of the team but also a comment on the growth of the sector as a whole. This investment will go towards continuing to turn Team Vitality into a global esports brand and we look forward to providing further updates on our future wins as we continue to pursue V for Victory.”
Amit Jain, Principal at Rewired.GG commented:
“Any industry with an audience that’s growing rapidly into hundreds of millions is hugely exciting and esports is no exception. We’ve seen the current esports trend many times before in the tech sector: first the number of eyeballs grows exponentially, and then full monetization comes later. We believe that esports is one of the world’s fastest growing industries today, and the success of teams like Team Vitality show that there is real opportunity for growth in this market. We are well on the way to building one of the world’s first billion-dollar esports teams.”
-ends-
Footnotes and References
*BBC
Video of esports world champion, Rocket League player Kyle ‘Scrub Killa’ Robertson, and esports super-coach Mike ‘Gregan’ Ellis, are available to embed into stories relating to this release, using these links:
Gregan: https://youtu.be/uLN4S1LFVgI
Scrub Killa: https://youtu.be/LSg-rwTeBHk
Images are available to download here and must be attributed to: Team Vitality: https://drive.google.com/drive/folders/1Ol4_J_pdo8S7c6W-YZ8tkgTrfOFPd4Xd
About Rewired.GG
Rewired.GG is an esports venture fund investing in the talent and ideas that are driving the global growth of esports. In November Rewired.GG 2018 backed European esports leader Team Vitality with €20m of investment to create a global esports brand. The investment thesis of the Rewired.GG esports venture fund is that esports is at an exciting tipping point. The NFL earns around $50 per fan, but that number for esports is only $3.20*. Rewired.GG predicts that this upside potential revenue growth per fan combined with rapidly growing global audiences with rapidly-growing spending power, will generate significant future returns.
About Team Vitality
Team Vitality is an international esports organisation that was founded by Nicolas Maurer and Fabien Devide in 2013. The team has players from ten different nationalities and boasts some of the biggest players in the world, including the world No.1 Fifa player, world No.1 CS:GO player, and the world champion Rocket League squad. Team Vitality players compete in a portfolio of 9 games with 10 competitive teams. Team Vitality's main League of Legends roster competes in the League of Legends European Championship (LEC), which they joined after purchasing Gambit Gaming's spot. They are sponsored by Orange, Red Bull, Renault and Adidas.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005183/en/
Contact information
To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff (Buchanan Communications)
rewired@buchanan.uk.com
+44 207 466 5000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom